University status and response to COVID-19
Please click on the link below for the latest health information:
Podcast: Meet our researchers
Trial investigating potential treatment for fatigue relief in people with long COVID reports results
17 April 2023
Researchers from the University of Oxford have reported findings from a Phase 2 clinical trial investigating the efficacy of an investigational treatment against long COVID fatigue. The study (reported in Lancet eClinical Medicine) found participants given the treatment, developed by US pharmaceutical company Axcella Therapeutics, reported feeling less fatigued than those given a placebo.
R21/Matrix-M™ malaria vaccine developed by University of Oxford receives regulatory clearance for use in Ghana
14 April 2023
The University of Oxford-developed and Serum Institute of India PvT Ltd (SIIPL)- manufactured and scaled up R21/Matrix-MTM malaria vaccine, leveraging Novavax’s adjuvant technology, has been licensed for use in Ghana by the country’s Food and Drugs Authority.
Deep Proteomics Network and Machine Learning Analysis of Human Cerebrospinal Fluid in Japanese Encephalitis Virus Infection.
Bharucha T. et al, (2023), J Proteome Res
An enrichment protocol and analysis pipeline for long read sequencing of the hepatitis B virus transcriptome
Ng E. et al, (2023), Journal of General Virology, 104
DEcancer: Machine learning framework tailored to liquid biopsy based cancer detection and biomarker signature selection
Halner A. et al, (2023), iScience, 26, 106610 - 106610
An ACAT inhibitor suppresses SARS-CoV-2 replication and boosts antiviral T cell activity.
Wing PAC. et al, (2023), PLoS pathogens, 19
Tau filaments are tethered within brain extracellular vesicles in Alzheimer's disease.
Fowler SL. et al, (2023), bioRxiv
Evaluation of T cell responses to naturally processed variant SARS-CoV-2 spike antigens in individuals following infection or vaccination.
Yin Z. et al, (2023), Cell Rep, 42